CWCorinne E. Wessner

Corinne E. Wessner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Corinne E. Wessner has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Early Breast Cancer Response to Chemotherapy with Ultrasound Radiomics

    by Swapnil Dolui, Basak Dogan, Corinne Wessner, Jessica Porembka, Priscilla Machado, Bersu Ozcan, Nisha Unni, Maysa Abu Khalaf, Flemming Forsberg, Kibo Nam, et al.

    Objective: This prospective study investigated the use of H-scan ultrasound (US) imaging as a novel component of a multiparametric radiomic analysis framework for characterizing human breast cancer response to neoadjuvant chemotherapy (NAC) before and early after treatment initiation. Methods: Thirty breast cancer patients scheduled for NAC were scanned using a clinical US system (Logiq E9, GE HealthCare) equipped with a 9L-D linear array transducer. Radiofrequency (RF) data was obtained at baseline (pre-NAC) and after 10% and 30% of the complete dose of chemotherapy. The RF data was analyzed by a bank of 256 frequency-shifted bandpass filters to form H-scan US frequency images. Grayscale texture features were extracted from both B-scan and H-scan US images. In addition, US attenuation coefficient and speckle statistics based on the Nakagami and Burr distributions were estimated from the RF data. Data classification of tumor and peri-tumoral regions was performed using a novel three-dimensional (3D) score map based on support vector machine (SVM) modeling. Unlike conventional classifiers that report only a single prediction score, a 3D score map provides a visual representation of the classifier decision space, enabling interpretation of class separation and treatment-induced shifts in multiparametric US measurements. Results: The dataset was split into 10 disjoint partitions (90% training, 10% testing) to compute area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy measures. Actual patient response to NAC was assessed at surgery and categorized as either pathologic complete response (pCR) or non-pCR. Multiparametric US and data classification results at pre-NAC found AUC values of 0.78 after using only tumor information (p < 0.01), which increased to 0.81 with inclusion of peri-tumoral information (p < 0.01). Significant differences in multiparametric US measures from both cancer response types was found after integration of patient data collected at 10% completion of the NAC regimen (i.e., first NAC cycle), yielding an improved AUC of 0.86 (p < 0.001). Conclusions: Multiparametric US imaging with radiomic features from both the tumor and peri-tumoral regions is a promising noninvasive approach for monitoring early breast cancer response to NAC.


  • Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial

    by Corinne E. Wessner, Flemming Forsberg, Andrej Lyshchik, Patrick O’kane, Kristen Bradigan, Ji-Bin Liu, Lauren J. Delaney, Kevin Anton, Stephen R. Topper, Jesse Civan, et al.

    Compared with treatment with only 90Y–transarterial radioembolization (TARE), adding microbubble-based radiosensitization via ultrasound-triggered microbubble destruction to 90Y-TARE had similar safety, provided improved treatment response, and prolonged survival in participants with hepatocellular carcinoma.


  • Open Access

    Noninvasive Diagnosis of Chronic Exertional Compartment Syndrome With Shear Wave Elastography and Subharmonic‐Aided Pressure Estimation

    by Corinne E. Wessner, Corbin Pomeranz, Rachel Blackman, Michael K. Hoy, Kristen Bradigan, Stephen A. Stache, Marc Harwood, Levon Nazarian, Flemming Forsberg

    Objective: Chronic exertional compartment syndrome (CECS) is an underdiagnosed condition that affects young athletes. CECS is caused by increased compartmental pressure in the fascial spaces during exercise. CECS is diagnosed by direct pressure readings (in mmHg), which is a painful and invasive test. Noninvasive shear‐wave elastography (SWE) and subharmonic‐aided pressure estimation (SHAPE) using contrast‐enhanced ultrasound were compared to compartment pressure testing for the diagnosis of CECS. Methods: Ten healthy volunteers and five CECS patients enrolled in this prospective, IRB‐approved pilot study. Subjects were scanned pre‐ and post‐exercise using a modified LOGIQ E10 scanner (GE HealthCare). For SWE, muscle stiffness was expressed as median shear velocity over 12 measurements. Following intravenous infusion of Definity (3 mL in 50 mL of saline; Lantheus Medical Imaging) SHAPE power was optimized, and three 5‐second clips were acquired. SWE and SHAPE pre‐to‐post differences were calculated offline and compared to CECS pressure testing (the reference). Results: In the healthy volunteers, pre‐ versus post‐exercise SWE showed a median velocity of 1.16 ± 0.17 versus 1.28 ± 0.22 m/s ( P = .01). In the CECS patients, the difference was 1.11 ± 0.11 versus 1.41 ± 0.19 m/s ( P = .06). However, there were no SWE differences between healthy volunteers and CECS patients ( P = .14). For pre‐ and post‐exercise SHAPE, both healthy volunteers and CECS patients demonstrated significant differences (−62.9 ± 2.09 vs –58.7 ± 2.74 dB and −59.0 ± 2.96 vs −50.8 ± 2.22 dB, respectively; P < .002). Healthy volunteers were statistically significantly different from CECS patients (4.2 ± 2.56 vs 8.1 ± 2.12 dB; P = .01). The SHAPE gradient correlated with compartment pressure testing ( r = −0.95; P = .01). Conclusions: These preliminary results indicate that SHAPE may become a noninvasive alternative for diagnosing CECS.


  • Microbubble encapsulation of monocarboxylate transporter 1 inhibitor AZD3965 for ultrasound mediated delivery to head and neck squamous cell carcinoma

    by Brian E. Oeffinger, Valeria Arango-Aliaga, Corinne E. Wessner, Hebah Falatah, Quezia Lecerda, Ankit S. Patel, Gagan Kaushal, Ji-Bin Liu, Ubaldo E. Martinez-Outschoorn, John R. Eisenbrey, et al.


  • Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI

    by Andrej Lyshchik, Cristina Kuon Yeng Escalante, Tania Siu Xiao, Fabio Piscaglia, Yuko Kono, Alexandra Medellin-Kowalewski, Shuchi K. Rodgers, Virginia Planz, Aya Kamaya, David T. Fetzer, et al.

    Contrast-enhanced US Liver Imaging Reporting and Data System (LI-RADS) could resolve some indeterminate liver observations (categorized as LR-4 and LR-M at CT or MRI), having a particularly high clinical effect for observations measuring at least 20 mm.


  • Open Access

    Combining CEUS and CT/MRI LI-RADS major imaging features: diagnostic accuracy for classification of indeterminate liver observations in patients at risk for HCC

    by Tania Siu Xiao, Cristina Mariuxi Kuon Yeng Escalante, Aylin Tahmasebi, Yuko Kono, Fabio Piscaglia, Stephanie R. Wilson, Alexandra Medellin-Kowalewski, Shuchi K. Rodgers, Virginia Planz, Aya Kamaya, et al.

    Purpose: To determine the diagnostic accuracy of combining CEUS and CT/MRI LI-RADS major imaging features for the improved categorization of liver observations indeterminate on both CT/MRI and CEUS. Materials and methods: A retrospective analysis using a database from a prospective study conducted at 11 centers in North America and Europe from 2018 to 2022 included a total of 109 participants at risk for HCC who had liver observations with indeterminate characterization (LR3, LR-4, and LR-M) on both CEUS and CT/MRI. The individual CEUS and CT/MRI LI-RADS major features were extracted from the original study and analyzed in various combinations. Reference standards included biopsy, explant histology, and follow-up CT/MRI. The diagnostic performance of the combinations of LI-RADS major features for definitive diagnosis of HCC was calculated. A reverse, stepwise logistical regression sub-analysis was also performed. Results: This study included 114 observations indeterminate on both CT/MRI and CEUS. These observations were categorized as LR-3 (n = 37), LR-4 (n = 41), and LR-M (n = 36) on CT/MRI and LR-3 (n = 48), LR-4 (n = 36), LR-M (n = 29), and LR-TIV (n = 1) on CEUS. Of them, 43.0% (49/114) were confirmed as HCC, 37.3% (43/114) non-malignant, and 19.3% (22/114) non-hepatocellular malignancies. The highest diagnostic accuracy among the combinations of imaging features was achieved in CT/MRI LR-3 observations, where the combination of CEUS arterial phase hyper-enhancement (APHE) + CT/MRI APHE had 96.7% specificity, 75.0% positive predictive value (PPV), and 86.5% accuracy for HCC. Conclusion: The combination of LI-RADS major features on CT/MRI and CEUS showed higher specificity, PPV, and accuracy compared to individual modalities' assessments, particularly for CT/MRI LR-3 observations.


  • Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial

    by Esika Savsani, Colette M. Shaw, Flemming Forsberg, Corinne E. Wessner, Andrej Lyshchik, Patrick O'Kane, Ji-Bin Liu, Rashmi Balasubramanya, Christopher G. Roth, Haresh Naringrekar, et al.

    Background Contrast-enhanced (CE) US has been studied for use in the detection of residual viable hepatocellular carcinoma (HCC) after locoregional therapy, but multicenter data are lacking. Purpose To compare two-dimensional (2D) and three-dimensional (3D) CE US diagnostic performance with that of CE MRI or CT, the current clinical standard, in the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective multicenter trial. Materials and Methods Participants aged at least 21 years with US-visible HCC scheduled for TACE were consecutively enrolled at one of three participating academic medical centers from May 2016 to March 2022. Each underwent baseline 2D and 3D CE US before TACE, 2D and 3D CE US 1-2 weeks and/or 4-6 weeks after TACE, and CE MRI or CT 4-6 weeks after TACE. CE US and CE MRI or CT were evaluated by three fellowship-trained radiologists for the presence or absence of viable tumors and were compared with reference standards of pathology (18%), angiography on re-treatment after identification of residual disease at 1-2-month follow-up imaging (31%), 4-8-month CE MRI or CT (42%), or short-term (approximately 1-2 months) CE MRI or CT if clinically decompensated and estimated viability was greater than 50% at imaging (9%). Diagnostic performance criteria, including sensitivity and specificity, were obtained for each modality and time point with generalized estimating equation analysis. Results A total of 132 participants were included (mean age, 64 years ± 7 [SD], 87 male). Sensitivity of 2D CE US 4-6 weeks after TACE was 91% (95% CI: 84, 95), which was higher than that of CE MRI or CT (68%; 95% CI: 58, 76; P < .001). Sensitivity of 3D CE US 4-6 weeks after TACE was 89% (95% CI: 81, 94), which was higher than that of CE MRI or CT (P < .001), with no evidence of a difference from 2D CE US (P = .22). CE MRI or CT had 85% (95% CI: 76, 91) specificity, higher than that of 4-6-week 2D and 3D CE US (70% [95% CI: 56, 80] and 67% [95% CI: 53, 78], respectively; P = .046 and P = .023, respectively). No evidence of differences in any diagnostic criteria were observed between 1-2-week and 4-6-week 2D CE US (P > .21). Conclusion The 2D and 3D CE US examinations 4-6 weeks after TACE revealed higher sensitivity in the detection of residual HCC than CE MRI or CT, albeit with lower specificity. Importantly, CE US performance was independent of follow-up time. Clinical trial registration no. NCT02764801 © RSNA, 2023 Supplemental material is available for this article.


  • Open Access

    Identification of sentinel lymph nodes in esophageal cancer patients using contrast-enhanced EUS with peritumoral injections

    by Ji-Bin Liu, Priscilla Machado, John R. Eisenbrey, Sriharsha Gummadi, Flemming Forsberg, Corinne E. Wessner, Anand Raman Kumar, Austin Chiang, Anthony Infantolino, Alexander Schlachterman, et al.

    Objectives: The objective of this pilot study was to compare the performance of contrast-enhanced EUS (CE-EUS)–guided fine-needle aspiration (FNA) with EUS-FNA for lymph node (LN) staging in esophageal cancer. Methods: Thirty-seven subjects with esophageal cancer undergoing EUS staging were enrolled, and 30 completed this institutional review board–approved study. A Prosound F75 US system (Hitachi Medical Systems, Tokyo, Japan) with harmonic contrast imaging software and GF-UCT180 curvilinear endoscope (Olympus, Tokyo, Japan) was utilized. All LNs identified by standard EUS were first noted. Sonazoid (dose: 1 mL; GE Healthcare, Oslo, Norway) was administered peritumorally, and all enhanced LNs were recorded. Fine-needle aspiration was performed on LNs considered suspicious by EUS alone, as well as LNs enhanced on CE-EUS. Performance of each modality was compared using FNA cytology as reference standard. Results: A total of 132 LNs were detected with EUS, of which 59 showed enhancement on CE-EUS. Fifty-three LNs underwent FNA, and 22 LNs were determined to be malignant. Among the latter, 10 were considered suspicious by EUS, whereas the other 12 LNs underwent FNA only because of CE-EUS enhancement. Contrast-enhanced EUS showed enhancement in 19 of the 22 malignant LNs. The rate of metastatic node identification from EUS was 45% (10/22), and it was 86% (19/22; P = 0.008) for CE-EUS. Eight subjects (8/30 [27% of study total]) had nodal status upgraded by the addition of CE-EUS, which influenced LN staging and clinical management. Conclusions: Fine-needle aspiration of LNs identified by CE-EUS may increase metastasis positive rate by ruling out LNs not associated with the tumor drainage pattern. In addition, CE-EUS seems to identify more metastatic LNs that would not be biopsied under the standard EUS criteria.


  • Open Access

    Improved Tumor Control Following Radiosensitization with Ultrasound-Sensitive Oxygen Microbubbles and Tumor Mitochondrial Respiration Inhibitors in a Preclinical Model of Head and Neck Cancer

    by Quezia Lacerda, Hebah Falatah, Ji-Bin Liu, Corinne E. Wessner, Brian Oeffinger, Ankit Rochani, Dennis B. Leeper, Flemming Forsberg, Joseph M. Curry, Gagan Kaushal, et al.

    Tumor hypoxia (oxygen deficiency) is a major contributor to radiotherapy resistance. Ultrasound-sensitive microbubbles containing oxygen have been explored as a mechanism for overcoming tumor hypoxia locally prior to radiotherapy. Previously, our group demonstrated the ability to encapsulate and deliver a pharmacological inhibitor of tumor mitochondrial respiration (lonidamine (LND)), which resulted in ultrasound-sensitive microbubbles loaded with O2 and LND providing prolonged oxygenation relative to oxygenated microbubbles alone. This follow-up study aimed to evaluate the therapeutic response to radiation following the administration of oxygen microbubbles combined with tumor mitochondrial respiration inhibitors in a head and neck squamous cell carcinoma (HNSCC) tumor model. The influences of different radiation dose rates and treatment combinations were also explored. The results demonstrated that the co-delivery of O2 and LND successfully sensitized HNSCC tumors to radiation, and this was also enhanced with oral metformin, significantly slowing tumor growth relative to unsensitized controls (p < 0.01). Microbubble sensitization was also shown to improve overall animal survival. Importantly, effects were found to be radiation dose-rate-dependent, reflecting the transient nature of tumor oxygenation.


  • Ultrasound‐Based Machine Learning Approach for Detection of Nonalcoholic Fatty Liver Disease

    by Aylin Tahmasebi, Shuo Wang, Corinne E. Wessner, Trang Vu, Ji‐Bin Liu, Flemming Forsberg, Jesse Civan, Flavius F. Guglielmo, John R. Eisenbrey

    Objectives: Current diagnosis of nonalcoholic fatty liver disease (NAFLD) relies on biopsy or MR‐based fat quantification. This prospective study explored the use of ultrasound with artificial intelligence for the detection of NAFLD.Methods: One hundred and twenty subjects with clinical suspicion of NAFLD and 10 healthy volunteers consented to participate in this institutional review board‐approved study. Subjects were categorized as NAFLD and non‐NAFLD according to MR proton density fat fraction (PDFF) findings. Ultrasound images from 10 different locations in the right and left hepatic lobes were collected following a standard protocol. MRI‐based liver fat quantification was used as the reference standard with >6.4% indicative of NAFLD. A supervised machine learning model was developed for assessment of NAFLD. To validate model performance, a balanced testing dataset of 24 subjects was used. Sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy with 95% confidence interval were calculated.Results: A total of 1119 images from 106 participants was used for model development. The internal evaluation achieved an average precision of 0.941, recall of 88.2%, and precision of 89.0%. In the testing set AutoML achieved a sensitivity of 72.2% (63.1%–80.1%), specificity of 94.6% (88.7%–98.0%), positive predictive value (PPV) of 93.1% (86.0%–96.7%), negative predictive value of 77.3% (71.6%–82.1%), and accuracy of 83.4% (77.9%–88.0%). The average agreement for an individual subject was 92%.Conclusions: An ultrasound‐based machine learning model for identification of NAFLD showed high specificity and PPV in this prospective trial. This approach may in the future be used as an inexpensive and noninvasive screening tool for identifying NAFLD in high‐risk patients.